[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581157":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":65,"collaborators":7,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":7,"maxAge":7,"enrollmentInfo":76,"targetDuration":7,"studyType":79,"phases":7,"briefSummary":80,"conditions":81,"keywords":87,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Fabio Moda, PHD","Fondazione IRCCS Istituto Neurologico Carlo Besta","PRINCIPAL_INVESTIGATOR",[14,34,48],{"facility":15,"status":16,"city":17,"state":18,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP)","RECRUITING","Sesto Fiorentino","FI","50019","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],11.19924,43.83193,{"lat":26,"lon":25},[29],{"name":30,"role":31,"phone":32,"phoneExt":7,"email":33},"Linda Cerofolini, PHD","CONTACT","(+39) 3473555936","fragai@cerm.unifi.it",{"facility":35,"status":16,"city":36,"state":7,"zip":37,"country":20,"countryCode":21,"cosmosGeoPoint":38,"geoPoint":42,"contacts":43},"IRCCS Centro San Giovanni di Dio","Brescia","25125",{"type":23,"coordinates":39},[40,41],10.21472,45.53558,{"lat":41,"lon":40},[44],{"name":45,"role":31,"phone":46,"phoneExt":7,"email":47},"Claudia Saradeno, PHD","(+39) 0303501328","daniela.sarnataro1@gmail.com",{"facility":11,"status":16,"city":49,"state":7,"zip":50,"country":20,"countryCode":21,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Milan","20133",{"type":23,"coordinates":52},[53,54],12.59836,42.78235,{"lat":54,"lon":53},[57,61],{"name":10,"role":31,"phone":58,"phoneExt":59,"email":60},"+ 39 02.2394","2770","fabio.moda@istituto-besta.it",{"name":62,"role":31,"phone":63,"phoneExt":64,"email":7},"Arianna Ciullini, PHD","0039.02.2394","2249",{"type":66,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100581157","exploring-the-olfactory-mucosa-blood-and-urine-for-the-identification-of-early-biomarkers-of-parkinsons-disease-atypical-parkinsonisms-and-neurocognitive-disorders-due-to-lewy-body-disease-100581157",false,"NCT06846658","Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease","EXTRAORDINARY","Inclusion Criteria:\n\n* PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.\n\nExclusion Criteria:\n\n* na",true,"ALL",{"count":77,"type":78},180,"ESTIMATED","OBSERVATIONAL","Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages. Each disease is associated with distinct conformers of misfolded alpha-synuclein (maS) which form typical protein aggregates in the brain and represent key disease biomarkers. Thus, detection and characterization of intracerebral maS aggregates allow a definite diagnosis. The recent development of ultrasensitive assays enabled the detection of maS and other potential new biomarkers in peripheral tissues, although with several limitations. Here, the investigators propose to combine the expertise of leading and young researchers in the field of neurology, structural and molecular biology, biophysics and machine learning to perform ultrasensitive and multi-omics analyses of olfactory mucosa (OM), blood and urine of PD, MSA and DLB patients for detecting and characterizing key peripheral biomarkers allowing accurate disease recognition.",[82,83,84,85,86],"Parkinson Disease","MSA - Multiple System Atrophy","Lewy Body Dementia (LBD)","Neurodegenerative Disease","Healthy Subjects (HS)",[88,89,90,91,92,93,94,95,96,97,98,99,100,101,102],"Parkinson's disease (PD)","multiple system atrophy (MSA)","dementia with Lewy bodies (DLB)","misfolded alpha-synuclein","new biomarkers","peripheral tissues","Real-Time Quaking-Induced Conversion (RT-QuIC)","single-molecule array (Simoa)","circulating neurofilament light chain (NfL)","Nanoparticle Tracking Analysis (NTA)","blood-derived extracellular vesicles (EVs)","multi-omics analyses","transmission electron microscopy (TEM) and protein-NMR","protein misfolding","early diagnosis","2026-03-25",{"date":105,"type":106},"2026-03-30","ACTUAL",{"date":108,"type":106},"2023-10-03",{"date":110,"type":78},"2026-04",{"name":5,"class":6},3]